The new epidemiology of HIV-related kidney disease

Journal of AIDS and Clinical Research

Volumn 3, Issue SPL ISSUE4, 2012, Pages

  Mallipattu, Sandeep K ^a   Wyatt, Christina M ^a   He, John C ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AIDS; HCV; HIV

Indexed keywords

EID: 84875711719     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.S4-001     Document Type: Review

References (85)

1. Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, et al. (1984) Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310: 669-673.
2. Gardenswartz MH, Lerner CW, Seligson GR, Zabetakis PM, Rotterdam H, et al. (1984) Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 21: 197-204.
3. Pardo V, Aldana M, Colton RM, Fischl MA, Jaffe D, et al. (1984) Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 101: 429-434.
4. Carbone L, D'Agati V, Cheng JT, Appel GB (1989) Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med 87: 389-395.
5. Cantor KP, Weiss SH, Goedert JJ, Battjes RJ (1991) HTLV-I/II seroprevalence and HIV/HTLV coinfection among U.S. intravenous drug users. J Acquir Immune Defic Syndr 4: 460-467.
6. Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, et al. (2000) Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 11: 2079-2087.
7. Ross MJ, Fan C, Ross MD, Chu TH, Shi Y, et al. (2006) HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. J Acqui Immune Defic Syndr 42: 1-11.
8. Gupta SK, Eustace JA, Winston JA, Boydstun, II, Ahuja TS, et al. (2005) Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40: 1559-1585.
9. Szczech LA, Hoover DR, Feldman JG, Cohen MH, Gange SJ, et al. (2004) Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 199: 1199-1206.
10. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, et al. (2010) Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 24: 387-394.
11. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, et al. (2007) Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis 45: 1633-1639.
12. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, et al. (2010) Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121: 651-658.
13. Wyatt CM, Morgello S, Katz-Malamed R, Wei C, Klotman ME, et al. (2009) The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 75: 428-434.
14. Berliner AR, Fine DM, Lucas GM, Rahman MH, Racusen LC, et al. (2008) Observations on a cohort of HIV-infected patients undergoing native renal biopsy. Am J Nephrol 28: 478-486.
15. Ross MJ, Klotman PE, Winston JA (2000) HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDS 14: 637-645.
16. Fine DM, Perazella MA, Lucas GM, Atta MG (2008) Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J kidney Dis 51: 504-514.
17. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, et al. (2004) The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 66: 1145-1152.
18. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J kidney Dis 41: 1-12.
19. Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, et al. (2011) Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol 6: 1700-1707.
20. Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, et al. (2007) Chronic kidney disease in HIV infection: an urban epidemic. AIDS 21: 2101-2103.
21. Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, et al. (2009) Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 10: 329-336.
22. Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, et al. (2007) Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 45: 1593-1601.
23. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, et al. (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667-1678.
24. Walli R, Herfort O, Michl GM, Demant T, Jager H, et al. (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12: F167-173.
25. Brown TT, Li X, Cole SR, Kingsley LA, Palella FJ, et al. (2005) Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 19: 1375-1383.
26. Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, et al. (2007) Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 21: 1739-1745.
27. Yan Q, Hruz PW (2005) Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 40: 398-403.
28. Gallant JE, Parish MA, Keruly JC, Moore RD (2005) Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40: 1194-1198.
29. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG (2009) HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 23: 2143-2149.
30. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, et al. (2010) Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 53: 62-69.
31. Szczech LA, Edwards LJ, Sanders LL, van der Horst C, Bartlett JA, et al. (2002) Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 57: 336-341.
32. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, et al. (2007) Microalbuminuria in HIV infection. AIDS 21: 1003-1009.
33. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, et al. (2008) Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 197: 1548-1557.
34. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, et al. (2007) Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 18: 2968-2974.
35. Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, et al. (2010) A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 78: 698-704.
36. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, et al. (2010) Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345-350.
37. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, et al. (2011) APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. J Am Soc Nephrol 22: 2129-2137.
38. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44: S6-9.
39. Stokes MB, Chawla H, Brody RI, Kumar A, Gertner R, et al. (1997) Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis 29: 514-525.
40. Cheng JT, Anderson HL, Markowitz GS, Appel GB, Pogue VA, et al. (1999) Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 10: 1566-1574.
41. Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, et al. (2009) Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. Am J Kidney Dis 54: 43-50.
42. Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR (2008) The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 22: 1799-1807.
43. Izzedine H, Sene D, Cacoub P, Jansen H, Camous L, et al. (2009) Kidney diseases in HIV/HCV-co-infected patients. AIDS 23: 1219-1226.
44. Fischer MJ, Wyatt CM, Gordon K, Gibert CL, Brown ST, et al. (2010) Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 53: 222-226.
45. Korbet SM, Genchi RM, Borok RZ, Schwartz MM (1996) The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 27: 647-651.
46. Nochy D, Glotz D, Dosquet P, Pruna A, Guettier C, et al. (1993) Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 8: 11-19.
47. Gerntholtz TE, Goetsch SJ, Katz I (2006) HIV-related nephropathy: a South African perspective. Kidney Int 69: 1885-1891.
48. Winston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, et al. (2001) Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. New Engl J Med 344: 1979-1984.
49. Kirchner JT (2002) Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. AIDS Read 12: 103-105, 110-112.
50. Alsauskas ZC, Medapalli RK, Ross MJ (2011) Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother 12: 691-704.
51. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. New Engl J Med 355: 2283-2296.
52. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, et al. (2008) Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 149: 289-299.
53. Gagnon RF, Tecimer SN, Watters AK, Hatzakis GE, Tsoukas CM (2000) The natural history of leukocyturia associated with indinavir treatment in HIV+ individuals. Am J Nephrol 20: 448-454.
54. Dieleman JP, van Rossum AM, Stricker BC, Sturkenboom MC, de Groot R, et al. (2003) Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. J Acquir Immune Defic Syndr 32: 135-142.
55. Kopp JB, Falloon J, Filie A, Abati A, King C, et al. (2002) Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis 34: 1122-1128.
56. Martinez F, Mommeja-Marin H, Estepa-Maurice L, Beaufils H, Bochet M, et al. (1998) Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 13: 750-753.
57. Havlir DV, O'Marro SD (2004) Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 38: 1599-1604.
58. von Hentig N (2008) Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc) 44: 103-132.
59. Chang HR, Pella PM (2006) Atazanavir urolithiasis. N Engl J Med 355: 2158-2159.
60. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB (2007) Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 21: 1215-1218.
61. Atazanavir (Reyataz) (2003) Project Inform perspective 7-10.
62. Couzigou C, Daudon M, Meynard JL, Borsa-Lebas F, Higueret D, et al. (2007) Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis 45: e105-108.
63. Goicoechea M, Liu S, Best B, Sun S, Jain S, et al. (2008) Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197: 102-108.
64. Gallant JE, Moore RD (2009) Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23: 1971-1975.
65. Lewis W (2003) Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 58: 189-197.
66. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, et al. (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346: 811-820.
67. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, et al. (2005) Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20: 743-746.
68. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
69. Squires K, Pozniak AL, Pierone G, Steinhart CR, Berger D, et al. (2003) Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 139: 313-320.
70. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, et al. (2002) Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16: 1257-1263.
71. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, et al. (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5: 1048-1051.
72. Bendele RA, Richardson FC (2002) Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum Pathol 33: 574.
73. Gitman MD, Hirschwerk D, Baskin CH, Singhal PC (2007) Tenofovir-induced kidney injury. Expert Opin Drug Saf 6: 155-164.
74. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354: 251-260.
75. Antoniou T, Raboud JM, Kovacs C, Diong C, Brunetta J, et al. (2009) Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy. AIDS Care 21: 1247-1252.
76. Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, et al. (2007) Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic) 6: 178-187.
77. Fernando SK, Finkelstein FO, Moore BA, Weissman S (2008) Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci 335: 89-94.
78. Moreno S, Domingo P, Palacios R, Santos J, Falco V, et al. (2006) Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr 42: 385-387.
79. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, et al. (2004) Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 37: 1489-1495.
80. Winston JA, Shepp DH (2006) The role of drug interactions and monitoring in the prevention of tenofovir-associated kidney disease. Clin Infect Dis 42: 1657-1658.
81. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, et al. (2008) The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22: 2155-2163.
82. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21: 1273-1281.
83. Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, et al. (2007) Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12: 1165-1173.
84. Winston A, Amin J, Mallon P, Marriott D, Carr A, et al. (2006) Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7: 105-111.
85. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505.